Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-01-2022 | Acute Myeloid Leukemia | Images

Acute Promyelocytic Leukemia with t(2;3): An Unusual Additional Chromosomal Abnormality

Authors: Smeeta Gajendra, Anil Kumar Yadav, Manorama Bhargava

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2022

Abstract

Acute promyelocytic leukemia is a distinct subset of acute myeloid leukemia with characteristic clinical, morphological and genetic features. The gene product PML-RAR alpha resulting from reciprocal t(15;17) translocation, plays a pivotal role in the pathogenesis of acute promyelocytic leukemia and classified as favorable cytogenetic features. We are describing an unusual additional chromosomal abnormality t(2;3) in APL patient.

Stevens-Kroef M, Poppe B, van Zelderen-Bhola S, van den Berg E, van der Blij-Philipsen M et al (2004) Translocation t(2;3)(p15–23;q26–27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. Leukemia 18(6):1108–1114. https://doi.org/10.1038/sj.leu.2403346CrossRefPubMed

Nozza F, Vona G, Trino S, D’Auria F, La Rocca F, Grieco V et al (2019) A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain. Mol Cytogenet 5(12):32. https://doi.org/10.1186/s13039-019-0445-1CrossRef

Title: Acute Promyelocytic Leukemia with t(2;3): An Unusual Additional Chromosomal Abnormality
Authors: Smeeta Gajendra
Anil Kumar Yadav
Manorama Bhargava
Publication date: 01-01-2022
Publisher: Springer India
Keywords: Acute Myeloid Leukemia
Acute Promyelocytic Leukemia
Chromosomal Abnormality
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 1/2022
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-021-01468-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Outcomes of HIDAC 18 g Versus IDAC 9 g in Consolidation Therapy of Acute Myeloid Leukemia: A Retrospective Study

First Observation of Compound Heterozygosity for Hb S/Hb Lepore-Hollandia in India

Serum Vascular Endothelial Gowth Factor Correlates with Hasford Score in Chronic Myeloid Leukemia

Successful Use of High Dose Methotrexate in Treatment of Primary CNS Lymphoma Patients Without Access to Serum Methotrexate Levels Monitoring: Challenges and Outcome

Iatrogenic Immunodeficiency Associated Lymphoproliferative Disorder in Patients with Acute Lymphoblastic Leukemia:A Case Series

Performance Evaluation of Fully Automated 5-Part Differential Hematology Analyzer ELite 580 (ERBA)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer